Topical Treatment of Kaposi’s Sarcoma, Basal Cell Carcinoma and Solar Keratosis with Ointment of BCG and Cord Factor

Dermatology ◽  
1979 ◽  
Vol 158 (2) ◽  
pp. 117-125 ◽  
Author(s):  
Haim A. Cohen ◽  
Adam Bekierkunst
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Topical Treatment ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Solar Keratosis ◽  
Cord Factor

Telomerase Activity in Kaposi's Sarcoma, Squamous Cell Carcinoma, and Basal Cell Carcinoma

2001 ◽  
Vol 226 (8) ◽  
pp. 753-757 ◽  
Author(s):  
Ziping Chen ◽  
Kathleen J. Smith ◽  
Henry G. Skelton ◽  
Terry L. Barrett ◽  
Herbert T. Greenway ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Basal Cell ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Telomerase Activity

scholarly journals Formulations Based on Drug Loaded Aptamer-Conjugated Liposomes as a Viable Strategy for the Topical Treatment of Basal Cell Carcinoma—In Vitro Tests

Pharmaceutics ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 866
Author(s):  
Anca N. Cadinoiu ◽  
Delia M. Rata ◽  
Leonard I. Atanase ◽  
Cosmin T. Mihai ◽  
Simona E. Bacaita ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Topical Treatment ◽  
Skin Irritation ◽  
In Vitro Tests ◽  
Liposomal Drug ◽  
Liposomal Formulations ◽  
As1411 Aptamer

Topical liposomal drug formulations containing AS1411-aptamer conjugated liposomes were designed to deliver in a sustained way the 5-fluorouracil to the tumor site but also to increase the compliance of patients with basal cell carcinoma. The 5-fluorouracil penetrability efficiency through the Strat-M membrane and the skin irritation potential of the obtained topical liposomal formulations were evaluated in vitro and the Korsmeyer Peppas equation was considered as the most appropriate to model the drug release. Additionally, the efficiency of cytostatic activity for targeted antitumor therapy and the hemolytic capacity were performed in vitro. The obtained results showed that the optimal liposomal formulation is a crosslinked gel based on sodium alginate and hyaluronic acid containing AS1411-aptamer conjugated liposomes loaded with 5-fluorouracil, which appeared to have favorable biosafety effects and may be used as a new therapeutic approach for the topical treatment of basal cell carcinoma.

scholarly journals Imiquimod 5% cream in the treatment of superficial and nodular basal cell carcinomas: study of 10 cases

2002 ◽  
Vol 77 (6) ◽  
pp. 693-698 ◽  
Author(s):  
Cyro Festa Neto
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Topical Treatment ◽  
Imiquimod Cream ◽  
Basal Cell Carcinomas ◽  
Different Types

BACKGROUND: Topical treatment with 5% imiquimod cream has been demonstrated to be effective in patients with basal cell carcinoma. OBJECTIVES: In the present study, efficacy and tolerability of this treatment was analyzed in 10 patients with 13 different types of superficial and nodular basal cell carcinomas. METHODS: Imiquimod cream was applied daily for a mean period of 23 days. RESULTS AND CONCLUSIONS: All patients responded favorably to the drug with healing of the lesions. No recurrence was observed during two to three months of follow up.

scholarly journals Topical Treatment of Basal Cell Carcinomas in Nevoid Basal Cell Carcinoma Syndrome with a Smoothened Inhibitor

2011 ◽  
Vol 131 (8) ◽  
pp. 1735-1744 ◽  
Author(s):  
Hans Skvara ◽  
Frank Kalthoff ◽  
Josef G. Meingassner ◽  
Barbara Wolff-Winiski ◽  
Heinrich Aschauer ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Topical Treatment ◽  
Basal Cell Carcinomas

scholarly journals Imiquimod 5% cream in topical treatment of facial basal cell carcinoma

2015 ◽  
Vol 2 (1) ◽  
pp. 184-188
Author(s):  
Svetlana Grubor ◽  
Vesna Tatljak-Vlahovic ◽  
Biljana Radojevic
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Topical Treatment

FC24 LDE225, a specific smoothened inhibitor, for the topical treatment of nevoid basal cell carcinoma syndrome (Gorlinʼs syndrome)

2010 ◽  
Vol 20 ◽  
pp. e40 ◽  
Author(s):  
A. Stuetz ◽  
M.A. de Rie ◽  
H. Skvara ◽  
L. Mickel ◽  
C. Schuster ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Topical Treatment
Sign in / Sign up

Export Citation Format

Share Document